Cards Acccepted | 5% OFF Crypto | 3rd Party Testing | FREE Worldwide Shipping $400+
Menu
Cart
retatrutide 10-30 mg lyophilized vial
lyophilized peptide vial box (white cap)
retatrutide certificate of analysis
retatrutide hplc

Retatrutide 10-30mg | 10 Vial Box

$600.00 – $1,150.00

Buy retatrutide 10-30 mg (one 10-vial box). Worldwide dispatch 7 – 14 days to the USA, UK, CA, AUS & NZ. All orders are shipped wholesale in unbranded packaging.

Bulk discounts
Quantity Bulk Discount Price
25%$570.00
3-57%$558.00
6-1010%$540.00
SKU: RET10Category:

Description

Retatrutide is a next-generation peptide designed to help manage blood sugar levels and support weight loss by mimicking natural hormones that regulate hunger and glucose. It’s currently undergoing clinical trials as a peptide therapy for obesity and blood sugar control in people with type 2 diabetes.

Minimum order quantity: one box (10 vials x 10 – 30mg). Photo for illustration purposes only.

Additional information

Purity

≥99.0%

Molar Mass

4731.33

Molecular Formula

C₂₂₇H₃₅₄N₄₈O₆₉

Sequence

Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Strength

10MG, 20MG, 30MG

  1. Jastreboff, Ania M., et al. "Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial." New England Journal of Medicine 389.6 (2023): 514-526.
  2. Rosenstock, Julio, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet 402.10401 (2023): 529-544.
  3. Doggrell, Sheila A. "Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?." Expert opinion on investigational drugs 32.5 (2023): 355-359.
  4. Urva, Shweta, et al. "The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying." Diabetes, Obesity and Metabolism 25.9 (2023): 2784-2788.
  5. Kaur, Manmeet, and Saurav Misra. "A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity." European Journal of Clinical Pharmacology 80.5 (2024): 669-676.

Retatrutide CoA

Retatrutide HPLC

Related products